A new report on biopharma venture financing argues corporate venture capital (CVC) is reshaping ownership and funding dynamics, shifting how capital is allocated through Series B and beyond. The piece cites a British Business Bank commitment to Molten Ventures’ Growth Fund and points to evidence that a large share of post-2022 US IPO biopharma companies and pharma acquisitions have corporate investors on their cap tables. Industry executives quoted in the report describe CVC’s role as providing “permanent capital” and complementary corporate expertise, while also highlighting that not all CVC models operate through the same dealmaking structures. For biotech operators, the message is concrete: cap table composition and strategic investor behaviors are becoming an increasingly important variable in financing terms and downstream partnership options.